JPWO2021015221A1 - - Google Patents

Info

Publication number
JPWO2021015221A1
JPWO2021015221A1 JP2021534059A JP2021534059A JPWO2021015221A1 JP WO2021015221 A1 JPWO2021015221 A1 JP WO2021015221A1 JP 2021534059 A JP2021534059 A JP 2021534059A JP 2021534059 A JP2021534059 A JP 2021534059A JP WO2021015221 A1 JPWO2021015221 A1 JP WO2021015221A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534059A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021015221A1 publication Critical patent/JPWO2021015221A1/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
JP2021534059A 2019-07-22 2020-07-22 Pending JPWO2021015221A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019134766 2019-07-22
PCT/JP2020/028375 WO2021015221A1 (ja) 2019-07-22 2020-07-22 光学活性な１，４－ベンゾチアゼピン－１－オキシド誘導体の製造方法

Publications (1)

Publication Number Publication Date
JPWO2021015221A1 true JPWO2021015221A1 (ja) 2021-01-28

Family

ID=74193430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534059A Pending JPWO2021015221A1 (ja) 2019-07-22 2020-07-22

Country Status (5)

Country Link
US (1) US20220324856A1 (ja)
EP (1) EP4019089A4 (ja)
JP (1) JPWO2021015221A1 (ja)
TW (1) TWI827866B (ja)
WO (1) WO2021015221A1 (ja)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
AU2010219044B2 (en) 2009-02-25 2012-10-04 Noboru Kaneko 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same
JP2010195759A (ja) * 2009-02-25 2010-09-09 Noboru Kaneko １，４−ベンゾチアゼピン誘導体並びにその製造方法及びその用途
WO2010114563A1 (en) * 2009-04-03 2010-10-07 Sequel Pharmaceuticals, Inc. Metabolites of k201 (jtv-519) (4- [3-{1- (4- benzyl) piperidinyl} propionyl] -7 -methoxy 2, 3, 4, 5-tetrahydro-1,4-benzothiazepine monohydrochloride
JP2012046430A (ja) * 2010-08-24 2012-03-08 Noboru Kaneko １，４−ベンゾチアゼピン−ｓ−オキシド誘導体、およびそれを用いた医薬組成物ならびにその用途
JP2012131710A (ja) * 2010-12-17 2012-07-12 Aetas Pharma Co Ltd 制癌剤耐性を有する癌細胞に対する抗腫瘍効果増強剤
CA2956699C (en) 2014-07-30 2020-09-29 Aetas Pharma Co., Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same
WO2019117116A1 (ja) * 2017-12-11 2019-06-20 株式会社アエタスファルマ １，４－ベンゾチアゼピン－１－オキシド誘導体の光学異性体を含む腎機能障害の改善薬

Also Published As

Publication number Publication date
WO2021015221A1 (ja) 2021-01-28
US20220324856A1 (en) 2022-10-13
EP4019089A1 (en) 2022-06-29
TWI827866B (zh) 2024-01-01
EP4019089A4 (en) 2023-11-01
TW202116766A (zh) 2021-05-01

Similar Documents

Publication Publication Date Title
BR112019017762A2 (ja)
BR112021017339A2 (ja)
BR112021013854A2 (ja)
BR112021018450A2 (ja)
BR112019016141A2 (ja)
AU2020104490A4 (ja)
BR112021017738A2 (ja)
BR112019016138A2 (ja)
BR112019016142A2 (ja)
BR112021018168A2 (ja)
BR112021017728A2 (ja)
BR112021017234A2 (ja)
BR112021017355A2 (ja)
BR112021017173A2 (ja)
BR112021018102A2 (ja)
BR112021017083A2 (ja)
BR112021017637A2 (ja)
BR112021008711A2 (ja)
BR112021018452A2 (ja)
BR112021012348A2 (ja)
BR112021018250A2 (ja)
BR112021018093A2 (ja)
BR112021018084A2 (ja)
BR112021013944A2 (ja)
BR112021013128A2 (ja)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230707